Humanized Monoclonal Anti-CD3 Antibody Visilizumab As Second-Line Therapy For Glucocorticoid-Refractory, Acute GVHD

Trial Profile

Humanized Monoclonal Anti-CD3 Antibody Visilizumab As Second-Line Therapy For Glucocorticoid-Refractory, Acute GVHD

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Jan 2014

At a glance

  • Drugs Visilizumab (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Sponsors PDL BioPharma
  • Most Recent Events

    • 06 Jan 2014 Status changed from active, no longer recruiting to discontinued.
    • 09 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top